✦ LIBER ✦

ICI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women — prospective combined analysis of two multicenter trials

✍ Scribed by A. Howell; C.K. Osborne; J.F.R. Robertson; S.E. Jones; L. Mauriac; M. Ellis; S. Come; I. Vergote; A. Budzar; S. Gertler

Book ID: 117658408
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 190 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)81042-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fulvestrant versus anastrozole for the t

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women : A prospective combined analysis of two multicenter trials

✍ John F. R. Robertson; C. Kent Osborne; Anthony Howell; Stephen E. Jones; Louis M 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

## Abstract ## BACKGROUND Fulvestrant (ICI 182,780) is a new type of estrogen receptor (ER) antagonist that down‐regulates the ER and has no known agonist effects. The authors report the prospectively planned combined analysis of data from 2 Phase III trials comparing fulvestrant 250 mg monthly (_

Fulvestrant versus anastrozole for the t

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma : A prospectively planned combined survival analysis of two multicenter trials

✍ Anthony Howell; John Pippen; Richard M. Elledge; Louis Mauriac; Ignace Vergote; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

Fulvestrant (Faslodex™) versus anastrozo

Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

✍ L. Mauriac; J.E. Pippen; J. Quaresma Albano; S.Z. Gertler; C.K. Osborne 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 196 KB

3. A randomized trial of the new specifi

3. A randomized trial of the new specific aromatase inhibitor ‘Arimidex’ (anastrozole) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC)

✍ W. Jonat; A. Howell; C.P. Blomqvist; W. Eiermann; G. Winblad; C.J. Tyrrell; L. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 435 KB

351 Two randomised trials establishing e

351 Two randomised trials establishing efficacy and tolerability of arimidex (ZD1033) in the treatment of postmenopausal women with advanced breast cancer (PABC)

✍ W. Jonat; A. Buzdar; A. Howell; S. Jones; C. Blomqvist; C. Vogel; W. Eirmann; P. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Anastrozole versus megestrol acetate in

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials

✍ Aman U. Buzdar; Walter Jonat; Anthony Howell; Stephen E. Jones; Carl P. Blomqvis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Medical University of BACKGROUND. This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and tolerability of anastrozole (1 or 10 mg once daily), a selective, nonsteroidal aromatase inhibitor administered orally, and megestrol ace